-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
In -X- _ O
2009 -X- _ O
, -X- _ O
there -X- _ O
was -X- _ O
an -X- _ O
influenza -X- _ O
pandemic -X- _ O
in -X- _ O
South -X- _ O
Korea. -X- _ O
The -X- _ O
aim -X- _ O
of -X- _ O
this -X- _ O
study -X- _ O
was -X- _ O
to -X- _ O
evaluate -X- _ O
the -X- _ O
epidemiological -X- _ B-Intervention
, -X- _ I-Intervention
clinical -X- _ I-Intervention
and -X- _ I-Intervention
laboratory -X- _ I-Intervention
characteristics -X- _ I-Intervention
of -X- _ O
this -X- _ B-Patient
infection -X- _ I-Patient
in -X- _ I-Patient
children -X- _ I-Patient
and -X- _ I-Patient
adults. -X- _ I-Patient
METHODS -X- _ O
: -X- _ O
We -X- _ O
evaluated -X- _ O
the -X- _ O
epidemiologic -X- _ B-Intervention
characteristics -X- _ I-Intervention
of -X- _ O
patients -X- _ B-Patient
infected -X- _ I-Patient
with -X- _ I-Patient
the -X- _ I-Patient
2009 -X- _ I-Patient
H1N1 -X- _ I-Patient
influenza -X- _ I-Patient
A -X- _ I-Patient
virus -X- _ I-Patient
( -X- _ I-Patient
4,463 -X- _ I-Patient
patients -X- _ I-Patient
, -X- _ I-Patient
age -X- _ I-Patient
range -X- _ I-Patient
from -X- _ I-Patient
2 -X- _ I-Patient
mo -X- _ I-Patient
to -X- _ I-Patient
86 -X- _ I-Patient
y -X- _ I-Patient
) -X- _ I-Patient
, -X- _ O
and -X- _ O
the -X- _ O
clinical -X- _ O
and -X- _ O
laboratory -X- _ O
findings -X- _ O
of -X- _ O
373 -X- _ B-Outcome
inpatients -X- _ I-Outcome
( -X- _ I-Outcome
80 -X- _ I-Outcome
/ -X- _ I-Outcome
217 -X- _ I-Outcome
children -X- _ I-Outcome
, -X- _ I-Outcome
≤ -X- _ I-Outcome
15 -X- _ I-Outcome
y -X- _ I-Outcome
, -X- _ I-Outcome
had -X- _ I-Outcome
pneumonia -X- _ I-Outcome
and -X- _ I-Outcome
36 -X- _ I-Outcome
/ -X- _ I-Outcome
156 -X- _ I-Outcome
adults -X- _ I-Outcome
, -X- _ I-Outcome
> -X- _ I-Outcome
16 -X- _ I-Outcome
y -X- _ I-Outcome
, -X- _ I-Outcome
had -X- _ I-Outcome
pneumonia -X- _ I-Outcome
) -X- _ I-Outcome
in -X- _ O
a -X- _ O
single -X- _ O
hospital -X- _ O
during -X- _ O
the -X- _ O
epidemic. -X- _ O
RESULTS -X- _ O
: -X- _ O
The -X- _ O
majority -X- _ B-Outcome
of -X- _ I-Outcome
infected -X- _ I-Outcome
patients -X- _ I-Outcome
( -X- _ I-Outcome
94 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
were -X- _ I-Outcome
less -X- _ I-Outcome
than -X- _ I-Outcome
40 -X- _ I-Outcome
y -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
greater -X- _ I-Outcome
than -X- _ I-Outcome
90 -X- _ I-Outcome
% -X- _ I-Outcome
of -X- _ I-Outcome
cases -X- _ I-Outcome
occurred -X- _ I-Outcome
during -X- _ I-Outcome
a -X- _ I-Outcome
two-month -X- _ I-Outcome
period. -X- _ I-Outcome
The -X- _ I-Outcome
rates -X- _ I-Outcome
of -X- _ I-Outcome
admission -X- _ I-Outcome
and -X- _ I-Outcome
pneumonia -X- _ I-Outcome
were -X- _ I-Outcome
8.4 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
373 -X- _ I-Outcome
/ -X- _ I-Outcome
4,463 -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
2.5 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
116 -X- _ I-Outcome
/ -X- _ I-Outcome
4,463 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
respectively. -X- _ I-Outcome
The -X- _ I-Outcome
rates -X- _ I-Outcome
of -X- _ I-Outcome
admission -X- _ I-Outcome
and -X- _ I-Outcome
pneumonia -X- _ I-Outcome
, -X- _ I-Outcome
total -X- _ I-Outcome
duration -X- _ I-Outcome
of -X- _ I-Outcome
fever -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
frequency -X- _ I-Outcome
of -X- _ I-Outcome
underlying -X- _ I-Outcome
diseases -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
values -X- _ I-Outcome
of -X- _ I-Outcome
C-reactive -X- _ I-Outcome
protein -X- _ I-Outcome
and -X- _ I-Outcome
erythrocyte -X- _ I-Outcome
sedimentation -X- _ I-Outcome
rate -X- _ I-Outcome
tended -X- _ I-Outcome
to -X- _ I-Outcome
increase -X- _ I-Outcome
as -X- _ I-Outcome
age -X- _ I-Outcome
increased -X- _ I-Outcome
; -X- _ I-Outcome
highest -X- _ I-Outcome
rates -X- _ I-Outcome
were -X- _ I-Outcome
found -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
≥ -X- _ I-Outcome
65 -X- _ I-Outcome
y -X- _ I-Outcome
group. -X- _ I-Outcome
Pneumonia -X- _ I-Outcome
was -X- _ I-Outcome
founded -X- _ I-Outcome
more -X- _ I-Outcome
boys -X- _ I-Outcome
than -X- _ I-Outcome
girls -X- _ I-Outcome
in -X- _ I-Outcome
children -X- _ I-Outcome
, -X- _ I-Outcome
but -X- _ I-Outcome
more -X- _ I-Outcome
female -X- _ I-Outcome
than -X- _ I-Outcome
male -X- _ I-Outcome
in -X- _ I-Outcome
adults. -X- _ I-Outcome
The -X- _ I-Outcome
adult -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
pneumonia -X- _ I-Outcome
had -X- _ I-Outcome
higher -X- _ I-Outcome
leukocyte -X- _ I-Outcome
counts -X- _ I-Outcome
with -X- _ I-Outcome
lower -X- _ I-Outcome
lymphocyte -X- _ I-Outcome
differentials -X- _ I-Outcome
than -X- _ I-Outcome
the -X- _ I-Outcome
group -X- _ I-Outcome
without -X- _ I-Outcome
pneumonia -X- _ I-Outcome
, -X- _ I-Outcome
as -X- _ I-Outcome
shown -X- _ I-Outcome
in -X- _ I-Outcome
children -X- _ I-Outcome
group. -X- _ I-Outcome
CONCLUSION -X- _ O
: -X- _ O
Our -X- _ O
results -X- _ O
suggest -X- _ O
that -X- _ O
the -X- _ O
immunologic -X- _ B-Outcome
reaction -X- _ I-Outcome
to -X- _ I-Outcome
viral -X- _ I-Outcome
insults -X- _ I-Outcome
may -X- _ I-Outcome
be -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
age -X- _ I-Outcome
, -X- _ I-Outcome
sex -X- _ I-Outcome
and -X- _ I-Outcome
underlying -X- _ I-Outcome
diseases -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
that -X- _ I-Outcome
unknown -X- _ I-Outcome
herd -X- _ I-Outcome
immunity -X- _ I-Outcome
may -X- _ I-Outcome
affect -X- _ I-Outcome
populations. -X- _ I-Outcome
The -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
underlying -X- _ I-Outcome
diseases -X- _ I-Outcome
, -X- _ I-Outcome
especially -X- _ I-Outcome
in -X- _ I-Outcome
older -X- _ I-Outcome
patients -X- _ I-Outcome
may -X- _ I-Outcome
have -X- _ I-Outcome
immunologic -X- _ I-Outcome
insufficiency -X- _ I-Outcome
that -X- _ O
is -X- _ O
associated -X- _ O
with -X- _ O
immunologic -X- _ O
consumption -X- _ O
by -X- _ O
the -X- _ O
underlying -X- _ O
diseases -X- _ O
. -X- _ O

